Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 3Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Capecitabine 124Temozolomide 123Specimen Handling 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × fedratinib × Clear all
NCT05127174 2025-12-04

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
12 enrolled
Myeloid

Myeloproliferative Disorders

NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡